Integrity Capital Management (HK)’s Eucrates Biomedical Acquisition Corp. Ordinary Shares EUCR Stock Holding History

Integrity Capital Management (HK)’s Portfolio EUCR Stock Details EUCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-9,755	Closed	-$96K	–	80
2022 Q1	$96K	Buy	+9,755	New	+$95.8K	0.49%	35

Other funds holding EUCR

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

ACM

Altium Capital Management New York $42M AUM

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

ECU

Eisler Capital (UK) London, United Kingdom $21.7B AUM 0.34% 1-Year Est. Return

SCM

Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

Integrity Capital Management (HK)'s EUCR Position: Q2 2022 in Review

Integrity Capital Management (HK) sold out of Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) in Q2 2022, closing a stake of 9,755 shares — an estimated $96K sold.

Integrity Capital Management (HK) first reported a position in EUCR in Q1 2022 and held it in 1 quarter. The position peaked at $96K in Q1 2022. 37 funds tracked by Wall St. Rank hold EUCR as of Q2 2022.

Integrity Capital Management (HK) reported no remaining Eucrates Biomedical Acquisition Corp. Ordinary Shares position as of Q2 2022 after selling out during the quarter.
Integrity Capital Management (HK) sold 9,755 Eucrates Biomedical Acquisition Corp. Ordinary Shares shares in Q2 2022, an estimated $96K.
Integrity Capital Management (HK) first reported a position in Eucrates Biomedical Acquisition Corp. Ordinary Shares in Q1 2022 and held it in 1 quarter.
Integrity Capital Management (HK)'s Eucrates Biomedical Acquisition Corp. Ordinary Shares position peaked at $96K in Q1 2022.
37 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Ordinary Shares as of Q2 2022.

Based on Integrity Capital Management (HK)'s 13F filing for Q2 2022, filed 28 Jul 2022.